U.S. gastroenterologists generally follow a step-up approach when treating Crohn’s disease patients that begins with safe, albeit often less efficacious, therapies (e.g., aminosalicylates) first line, before progressing to more-potent drugs, such as immunosuppressants and/or biologics. Among the biologics, the TNF-alpha inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie/Eisai’s Humira) have—and continue to be—the most widely used agents. However, over the past several years, the Crohn’s disease treatment landscape has witnessed the approval of two novel biologics (i.e., Takeda’s Entyvio and Janssen’s Stelara), leading to increasing competition among the biologics, and further expanding physicians’ treatment armamentarium.
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed Crohn’s disease patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed Crohn’s disease patients?
- How have Entyvio and Stelara been integrated into the treatment algorithm?
- What percentage of Crohn’s disease patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
- What percentage of Crohn’s disease patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated Crohn’s disease patients?
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world, patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing brand share.